You are viewing the site in preview mode

Skip to main content

Table 2 Medication classes by treatment line among those receiving anti-cancer treatment in the advanced stage ovarian cancer cohort (n=8,325)

From: A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer

  N (%) N (%) N (%) N (%) N (%)
All Lines (All treated patients) First Line Second Line Third Line Fourth Line or Higher
Total cancer treatment episodes with treatment lines observed, among incident cases, N (%)a,b,c,d 8325 (100%) 8325 (100%) 5335 (64.1%) 3711 (44.6%) 2487 (29.9%)
Alkylating Agents 5863 (70.43%) 5071 (60.91%) 2425 (45.45%) 1230 (33.14%) 1074 (43.18%)
 Carboplatin (platinum agent) 5055 (60.72%) 4243 (50.97%) 1926 (36.10%) 890 (23.98%) 819 (32.93%)
 Cisplatin (platinum agent) 1075 (12.91%) 546 (6.56%) 368 (6.90%) 257 (6.93%) 258 (10.37%)
 Cyclophosphamide 358 (4.30%) 122 (1.47%) 77 (1.44%) 68 (1.83%) 160 (6.43%)
 Ifosfamide/Mesna 44 (0.53%) 15 (0.18%) 14 (0.26%) 10 (0.27%) 17 (0.68%)
 Ifosfamide 39 (0.47%) 13 (0.16%) 13 (0.24%) 10 (0.27%) 16 (0.64%)
 Altretamine 17 (0.20%) ≤10 ≤10 ≤10 12 (0.48%)
 Melphalan ≤10 0 (0%) 0 (0%) ≤10 ≤10
 Oxaliplatin (platinum agent) 327 (3.93%) 207 (2.49%) 117 (2.19%) 65 (1.75%) 72 (2.90%)
Mitotic Inhibitors 5368 (64.48%) 4584 (55.06%) 2033 (38.11%) 975 (26.27%) 904 (36.35%)
 Paclitaxel (Taxane) 4892 (58.76%) 4160 (49.97%) 1734 (32.50%) 807 (21.75%) 715 (28.75%)
 Albumin bound paclitaxel 3506 (42.11%) 2888 (34.69%) 1182 (22.16%) 540 (14.55%) 543 (21.83%)
 Docetaxel (Taxane) 864 (10.38%) 533 (6.40%) 310 (5.81%) 155 (4.18%) 185 (7.44%)
 Vinorelbine 123 (1.48%) 18 (0.22%) 30 (0.56%) 31 (0.84%) 80 (3.22%)
Antimetabolites 2045 (24.56%) 799 (9.60%) 737 (13.81%) 558 (15.04%) 894 (35.95%)
 Gemcitabine 1416 (17.01%) 363 (4.36%) 413 (7.74%) 345 (9.30%) 651 (26.18%)
 Capecitabine 219 (2.63%) 86 (1.03%) 87 (1.63%) 55 (1.48%) 89 (3.58%)
 Pemetrexed 247 (2.97%) 46 (0.55%) 39 (0.73%) 41 (1.10%) 164 (6.59%)
Antineoplastic - Angiogenesis Inhibitors 1572 (18.88%) 524 (6.29%) 482 (9.03%) 429 (11.56%) 716 (28.79%)
 Bevacizumab 1567 (18.82%) 524 (6.29%) 481 (9.02%) 427 (11.51%) 712 (28.63%)
Antineoplastic - Hormonal and Related Agents 3102 (37.26%) 2095 (25.17%) 1679 (31.47%) 1146 (30.88%) 1148 (46.16%)
 Anastrozole 437 (5.25%) 177 (2.13%) 170 (3.19%) 111 (2.99%) 176 (7.08%)
 Letrozole 354 (4.25%) 103 (1.24%) 130 (2.44%) 97 (2.61%) 173 (6.96%)
 Exemestane 127 (1.53%) 41 (0.49%) 45 (0.84%) 43 (1.16%) 49 (1.97%)
 Leuprolide 45 (0.54%) 20 (0.24%) 17 (0.32%) 15 (0.40%) 23 (0.92%)
 Goserelin 10 (0.12%) ≤10 ≤10 ≤10 ≤10
 Triptorelin ≤10 0 (0%) 0 (0%) 0 (0%) ≤10
 Tamoxifen 425 (5.11%) 167 (2.01%) 150 (2.81%) 98 (2.64%) 153 (6.15%)
Antineoplastics Misc. ≤10 ≤10 ≤10 ≤10 ≤10
Topoisomerase I/II Inhibitors 1024 (12.30%) 292 (3.51%) 284 (5.32%) 257 (6.93%) 527 (21.19%)
 Topotecan 691 (8.30%) 104 (1.25%) 162 (3.04%) 179 (4.82%) 406 (16.32%)
 Irinotecan 220 (2.64%) 93 (1.12%) 78 (1.46%) 58 (1.56%) 99 (3.98%)
 Etoposide 184 (2.21%) 95 (1.14%) 46 (0.86%) 20 (0.54%) 61 (2.45%)
Antineoplastic - Antibodies 1684 (20.23%) 608 (7.30%) 537 (10.07%) 464 (12.50%) 744 (29.92%)
Antineoplastic Combinations ≤10 0 (0%) ≤10 ≤10 ≤10
Chemotherapy Rescue/Antidote Agents 340 (4.08%) 242 (2.91%) 159 (2.98%) 90 (2.43%) 91 (3.66%)
 Leucovorin 328 (3.94%) 239 (2.87%) 155 (2.91%) 87 (2.34%) 85 (3.42%)
Somatostatin 83 (1%) 28 (0.34%) 24 (0.45%) 26 (0.70%) 32 (1.29%)
Doxorubicin (Anthracycline) 1789 (21.49%) 418 (5.02%) 536 (10.05%) 485 (13.07%) 726 (29.19%)
Antineoplastic Antibiotics 1848 (22.20%) 468 (5.62%) 548 (10.27%) 488 (13.15%) 735 (29.55%)
Antineoplastic - Hedgehog Pathway Inhibitors 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Antineoplastic – Immunomodulators ≤10 ≤10 0 (0%) 0 (0%) 0 (0%)
Antineoplastic Radiopharmaceuticals 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Chemotherapy Adjuncts 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Immune-Checkpoint Inhibitors 63 (0.76%) 15 (0.18%) 16 (0.30%) 11 (0.30%) 35 (1.41%)
 Nivolumab 35 (0.42%) ≤10 12 (0.22%) ≤10 19 (0.76%)
 Pembrolizumab 21 (0.25%) ≤10 ≤10 ≤10 15 (0.60%)
 Atezolizumab 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Avelumab 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Ipilimumab 11 (0.13%) ≤10 ≤10 ≤10 ≤10
 Durvalumab 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Antineoplastic Enzyme Inhibitors/PARP inhibitors 572 (6.87%) 274 (3.29%) 196 (3.67%) 120 (3.23%) 209 (8.40%)
 Olaparib 83 (1%) ≤10 9 (0.17%) 12 (0.32%) 66 (2.65%)
 Rucaparib 23 (0.28%) 0 (0%) ≤10 ≤10 21 (0.84%)
 Niraparib 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Pazopanib 32 (0.38%) ≤10 ≤10 ≤10 13 (0.52%)
  1. Abbreviations: N Number, Misc. Miscellaneous
  2. a The cohort includes patients who had at least one ICD-9-CM or ICD-10 diagnosis code for ovarian cancer, were continuously enrolled in a health plan contributing data to the HIRD for at least six months, and were confirmed to have advanced ovarian cancer based on staging information from either a cancer registry or the HIRE Oncology data or met the predictive model algorithm for advanced stage ovarian cancer. Patients may have received multiple treatments during each treatment line and may have received cancer treatment prior to line 1 if they were dispensed prior to the advanced stage ovarian index date. Diagnoses are not linked to a specific prescription, and thus some of the record treatments may have been specified for other cancers, if a patient had multiple malignancies.
  3. bIncident cases are individuals for whom at least six months of data were available in the HIRD prior to the first diagnosis of ovarian cancer in claims.
  4. cStratum percentages based on total number of cases for all lines.
  5. dPatients with follow-up periods shorter than 28 days (specified segment length) were excluded from the treatment line related analyses.
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us